Biotech News
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 full-year net product sales guidance to $535 million–$545 million Partnered with World Champion
